P Vader
Overview
Explore the profile of P Vader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Labonia M, Estape Senti M, van der Kraak P, Brans M, Dokter I, Streef T, et al.
J Control Release
. 2024 Apr;
369:734-745.
PMID: 38604385
Despite research efforts being made towards preserving (or even regenerating) heart tissue after an ischemic event, there is a lack of resources in current clinical treatment modalities for patients with...
2.
van de Wakker S, van Oudheusden J, Mol E, Roefs M, Zheng W, Gorgens A, et al.
Eur J Pharm Biopharm
. 2021 Dec;
170:59-69.
PMID: 34864197
Extracellular vesicles (EVs) are phospholipid bilayer enclosed vesicles which play an important role in intercellular communication. To date, many studies have focused on therapeutic application of EVs. However, to progress...
3.
Jiang L, Vader P, Schiffelers R
Gene Ther
. 2017 Feb;
24(3):157-166.
PMID: 28140387
Nucleic acid-based drugs offer a potentially effective tool for treatment of a variety of diseases, including cancer, cardiovascular diseases, neurological disorders and infectious diseases. However, clinical applications are hindered by...
4.
PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
Kooijmans S, Fliervoet L, van der Meel R, Fens M, Heijnen H, van Bergen En Henegouwen P, et al.
J Control Release
. 2016 Jan;
224:77-85.
PMID: 26773767
Extracellular vesicles (EVs) are increasingly being recognized as candidate drug delivery systems due to their ability to functionally transfer biological cargo between cells. However, the therapeutic applicability of EVs may...
5.
van der Aa L, Vader P, Storm G, Schiffelers R, Engbersen J
J Control Release
. 2014 Aug;
195:11-20.
PMID: 25135792
In the development of potent polymeric gene carriers for gene therapy, a good interaction between the polymer and the nucleotide is indispensable to form small and stable polyplexes. Polymers with...
6.
Vader P, van der Aa L, Storm G, Schiffelers R, Engbersen J
Curr Top Med Chem
. 2011 Dec;
12(2):108-19.
PMID: 22196278
RNA interference is a technique to induce sequence-specific gene silencing, but is hampered by inefficient delivery of its mediator, short interfering RNA, into target cells. This review describes recent advances...
7.
Vader P, Crielaard B, van Dommelen S, van der Meel R, Storm G, Schiffelers R
J Control Release
. 2011 Oct;
160(2):211-6.
PMID: 21983283
Angiogenesis is an attractive target for cancer therapy, due to its central position in tumor growth and development. Vascular Endothelial Growth Factor (VEGF) and its receptors (VEGFRs) play a key...
8.
Vader P, van der Meel R, Symons M, Fens M, Pieters E, Wilschut K, et al.
Angiogenesis
. 2011 Jul;
14(4):457-66.
PMID: 21789714
Angiogenesis, the sprouting of new blood vessels from the pre-existing vasculature, is a well established target in anti-cancer therapy. It is thought that the Rho GTPase Rac1 is required during...
9.
van der Aa L, Vader P, Schiffelers R, Engbersen J
J Control Release
. 2011 May;
148(1):e85-6.
PMID: 21529647
No abstract available.
10.
van der Aa L, Vader P, Storm G, Schiffelers R, Engbersen J
J Control Release
. 2010 Dec;
150(2):177-86.
PMID: 21130817
By Michael addition polymerization of N,N'-cystaminebisacrylamide (CBA) with variable ratios of 4-amino-1-butanol (ABOL) and ethylene diamine (EDA) or triethylenetetramine (TETA), poly(amido amine) copolymers could be obtained with tunable charge densities....